• Equivalence of a Stable Liquid Glucagon Formulation with Freshly Reconstituted Lyophilized Glucagon
Equivalence of a Stable Liquid Glucagon Formulation with Freshly Reconstituted Lyophilized Glucagon


Researchers at the Massachusetts General Hospital Diabetes Research Center are recruiting subjects to determine if a new type of glucagon (Xeris Pharmaceuticals) has the same effect on blood glucose as Eli Lilly glucagon.

You may be eligible if:

• You are between 21 and 80 years old
• You have had type 1 diabetes for at least 1 year
• You are using an insulin pump


The study involves a short screening visit to determine if you qualify. If you chose to participate, you will be asked to complete one 8-10 hour study visit at the MGH Clinical Research Center. During the visit, two intravenous (IV) catheters, one in each arm, will be placed and your blood glucose will be adjusted to about 90 mg/dl using insulin and dextrose. Once your blood glucose is in range, we will administer one small dose (50 micrograms or 5% of a total rescue dose) of either Lilly glucagon or Xeris glucagon and take frequent blood samples from the IV. We will deliver the same size dose of the other type of glucagon and take more blood samples from the IV.


Parking validation and a meal will be provided. You will receive $50 for completing the screening visit and $250 for the study visit for a total of $300 compensation.

For more information please contact:
Courtney Balliro, Clinical Research Nurse
Phone: (617)726-1242
E-mail: cballiro@mgh.harvard.edu
Institution  –  MGH - Massachusetts General Hospital, Boston, MA
Principal Investigator  – Steven J Russell, MD, PhD
  
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Courtney A Balliro, RN
Email  – cballiro@partners.org
Phone  – 617-726-1242

About Type 1 Diabetes:
Type 1 diabetes accounts for 5 to 10 percent of all diagnosed cases of diabetes in the US. Type 1 diabetes usually develops in children or young adults, but can start at any age. It may also be known by a variety of other names, including the following:
  • insulin-dependent diabetes mellitus (IDDM)
  • juvenile diabetes
  • brittle diabetes
  • sugar diabetes
There are two forms of type 1 diabetes:
  • idiopathic type 1 diabetes - refers to rare forms of the disease with no known cause.
  • immune-mediated diabetes - an autoimmune disorder in which the body's immune system destroys, or attempts to destroy, the cells in the pancreas that produce insulin. Immune-mediated diabetes is the most common form of type 1 diabetes, and the one generally referred to as type 1 diabetes. The information on this page refers to this form of type 1 diabetes.